CXCL10 and COVID-19: IP-10, previously identified as a biomarker for COVID-19 severity, was significantly reduced in 10 mg/kg treated groups at 2 dpi compared to controls (p = .04329), and in both 1.0 mg/kg and 10 mg/kg groups at 7 / 8 dpi compared to 0.1 mg/kg dose (p = .041126 and p = .025947, respectively) (Fig 3M).